Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at Needham & Company LLC

Needham & Company LLC upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a research note published on Friday morning, Marketbeat Ratings reports. Needham & Company LLC currently has $46.00 target price on the specialty pharmaceutical company’s stock.

COLL has been the topic of several other research reports. Piper Sandler restated a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.80.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock opened at $32.91 on Friday. The firm has a market cap of $1.06 billion, a PE ratio of 14.19 and a beta of 0.82. The stock has a 50 day moving average of $30.57 and a 200 day moving average of $34.04. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical has a 12 month low of $28.39 and a 12 month high of $42.29.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of COLL. GAMMA Investing LLC lifted its holdings in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 792 shares during the last quarter. CWM LLC boosted its position in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares during the period. TD Private Client Wealth LLC boosted its position in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the period. Virtus Fund Advisers LLC bought a new position in shares of Collegium Pharmaceutical during the third quarter valued at approximately $72,000. Finally, AXA S.A. purchased a new stake in shares of Collegium Pharmaceutical in the second quarter worth approximately $209,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.